Tag: Neuroscience
PharmaSignal — Neuroscience therapeutic area
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
BioSpace
With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics.
Neurology, biomanufacturing start-ups bag UK AI funding
Pharmaphorum
The first recipients of the UK government’s 500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.
New data build case for Roche’s oral BTK drug for MS
Pharmaphorum
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
Tortugas debuts with $106M and brain drugs from Hansoh, Eisai
BioPharma Dive
Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs
BioSpace
With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
Trump executive order lifts psychedelics biotechs
BioPharma Dive
Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.
FDA Policy Tracker 2026: Psychedelics get a boost
BioSpace
A year of significant policy change at the FDA brought momentum and scrutiny into the new year.
Trump backs psychedelics for mental health in new executive order
Pharmaceutical Technology
Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.
UCB to purchase Neurona and NRTX-1001 for $1.15bn
Pharmaceutical Business Review
The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.
UCB to purchase Neurona and NRTX-1001 for $1.15bn
Pharmaceutical Technology
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.
UCB cuts $1.15bn deal to buy epilepsy biotech Neurona
Pharmaphorum
UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
Trump signs order to hasten psychedelic medicine access
Pharmaphorum
Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
Roche to start new Elevidys study following setback in Europe
BioPharma Dive
The Swiss drugmaker, which owns rights to the Duchenne gene therapy outside the U.S., hopes the trial will yield additional approvals in Europe and elsewhere.
Most patients “won’t see benefit” with Alzheimer’s drugs
Pharmaphorum
A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.
Parkinson’s charity partners Biognosys on biomarker project
Pharmaphorum
A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease.
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
BioSpace
GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to…
Alzheimer’s biotech Korsana to go public via reverse merger
Pharmaphorum
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s.
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Pharmaceutical Technology
Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.
Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout
BioPharma Dive
The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.
Otsuka grows in neuroplastogens with $1.225bn Transcend buy
Pharmaphorum
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.